Revista Española de Quimioterapia,
Journal Year:
2024,
Volume and Issue:
37(5), P. 369 - 386
Published: May 23, 2024
Prostheses
or
implantable
medical
devices
(IMDs)
are
parts
made
of
natural
artificial
materials
intended
to
replace
a
body
structure
and
therefore
must
be
well
tolerated
by
living
tissues.
The
types
IMDs
currently
available
usable
very
varied
capable
replacing
almost
any
human
organ.
A
high
but
imprecise
percentage
Spaniards
carriers
one
more
which
they
often
owe
their
quality
life
survival.
constructed
with
different
that
combined
in
the
same
prosthesis.
These
combine
harmlessness
tissues
wear
resistance.
Their
durability
depends
on
many
factors
both
host
type
prosthesis,
vast
majority
last
for
than
10-15
years
remain
function
lifetime
patient.
most
frequently
implanted
placed
heart
great
vessels,
joints,
dental
arches
breast
frequent
complications
classified
as
non-infectious,
particularly
loosening
intolerance,
infectious.
Complications,
when
occur,
lead
significant
increase
morbidity,
repair
replacement
multiplies
health
care
cost
and,
occasions,
can
cause
death
fight
against
IMD
is
focused
design
new
resistant
infection
use
antimicrobial
substances
released
from
these
materials.
production
requires
multidisciplinary
technical
teams,
also
willingness
part
industry
authorities
not
found
Spain
European
nations.
Scientific
prostheses
estimated
less
2%
world
total,
probably
below
what
corresponds
our
level
socio-economic
development.
future
involves,
among
other
factors,
examining
potential
role
Artificial
Intelligence
design,
knowledge
tissue
regeneration,
greater
efficiency
preventing
infections
taking
alternative
treatments
beyond
antimicrobials,
such
phage
therapy.
For
reasons,
Ramón
Areces
Foundation
convened
series
experts
fields
related
who
answered
discussed
questions
previously
formulated
Council.
following
lines
written
testimony
answers
them.
Journal of Clinical Investigation,
Journal Year:
2025,
Volume and Issue:
135(5)
Published: March 2, 2025
Bacteriophage
(phage)
therapy
has
emerged
as
a
promising
solution
to
combat
the
growing
crisis
of
multidrug-resistant
(MDR)
infections.
There
are
several
international
centers
actively
engaged
in
implementation
phage
therapy,
and
recent
case
series
have
reported
encouraging
success
rates
patients
receiving
personalized,
compassionate
for
difficult-to-treat
Nonetheless,
substantial
hurdles
remain
way
more
widespread
adoption
consistent
success.
This
Review
offers
comprehensive
overview
current
technologies
therapeutic
approaches.
We
first
delineate
common
steps
development,
from
bank
establishment
clinical
administration,
examine
spectrum
approaches,
personalized
fixed
cocktails.
Using
framework
conventional
drug
development
pipeline,
we
then
identify
critical
knowledge
gaps
areas
such
cocktail
design,
formulation,
pharmacology,
trial
design.
conclude
that,
while
holds
promise,
structured
pipeline
sustained
government
support
crucial
MDR
European Journal of Microbiology and Immunology,
Journal Year:
2024,
Volume and Issue:
14(1), P. 13 - 25
Published: Feb. 2, 2024
Staphylococcus
aureus
infections
have
already
presented
a
substantial
public
health
challenge,
encompassing
different
clinical
manifestations,
ranging
from
bacteremia
to
sepsis
and
multi-organ
failures.
Among
these
infections,
methicillin-resistant
S.
(MRSA)
is
particularly
alarming
due
its
well-documented
resistance
multiple
classes
of
antibiotics,
contributing
significantly
global
mortality
rates.
Consequently,
the
urgent
need
for
effective
treatment
options
has
prompted
growing
interest
in
exploring
phage
therapy
as
potential
non-antibiotic
against
MRSA
infections.
Phages
represent
class
highly
specific
bacterial
viruses
known
their
ability
infect
certain
strains.
This
review
paper
explores
phages
low
toxicity
auto-dosing
capabilities.
The
also
discusses
synergistic
effect
phage-antibiotic
combination
(PAC)
promising
results
vitro
animal
model
studies,
which
could
lead
extensive
human
trials.
However,
clinicians
establish
adhere
standard
protocols
governing
administration
implementation.
Prominent
trials
are
needed
develop
advance
intervention,
meeting
regulatory
guidelines,
logistical
requirements,
ethical
considerations,
potentially
revolutionizing
STAR Protocols,
Journal Year:
2024,
Volume and Issue:
5(2), P. 102949 - 102949
Published: April 30, 2024
Phage
therapy
has
re-emerged
as
a
promising
treatment
for
non-resolving
infections.
Given
the
lack
of
approved
phage
treatments,
there
is
need
to
establish
compassionate
use
pipeline.
Here,
we
present
protocol
matching,
treatment,
and
monitoring
bacteriophage
in
We
describe
steps
consultation
request
implementation,
evaluating
comparing
different
aspects
activity,
production.
then
detail
procedures
multidisciplinary
meetings,
ethics
approvals,
therapy,
follow-up.
For
complete
details
on
execution
this
protocol,
please
refer
Onallah
et
al.1,2
PEDIATRICS,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 11, 2025
Bacteriophages
are
highly
specific
in
targeting
single
pathogens
the
treatment
of
bacterial
infections
and
thus
offer
a
promising
alternative
to
antibiotic
therapies
with
potential
for
essentially
no
impact
child’s
own
microbiome.
have
been
evaluated
by
investigators
several
tissue
site
adults,
but
data
children
lacking.
The
application
this
therapy
pediatrics
provides
an
extraordinary
opportunity
redesign
our
approach
directed,
precision
medicine
antimicrobial
infants
both
acute
chronic
infections,
particularly
those
caused
multidrug-resistant
pathogens.
In
therapeutic
approach,
bacteriophage
preparation
would
be
selected
exclusively
limited
patient’s
pathogen,
minimizing
collateral
damage
microbiome,
as
often
demonstrated
therapy.
following
article,
we
describe
these
novel
anti-infective
biological
agents,
review
recent
literature,
discuss
practical
considerations
limitations,
share
applications
topical
systemic
administration
bacteriophages,
either
primary
or
combination
traditional
antibiotics.
Additionally,
important
areas
interest
pediatric
research
discussed.
Antibiotics,
Journal Year:
2025,
Volume and Issue:
14(3), P. 296 - 296
Published: March 12, 2025
Extensive
use
of
antibiotics
in
human
healthcare
as
well
agricultural
and
environmental
settings
has
led
to
the
emergence
spread
antibiotic-resistant
bacteria,
rendering
many
infections
increasingly
difficult
treat.
Coupled
with
limited
development
new
antibiotics,
rise
antimicrobial
resistance
(AMR)
caused
a
major
health
crisis
worldwide,
which
calls
for
immediate
action.
Strengthening
AMR
surveillance
systems
is,
therefore,
crucial
global
national
efforts
combating
this
escalating
threat.
This
review
explores
potential
metagenomics,
sequenced-based
approach
analyze
entire
microbial
communities
without
need
cultivation,
transformative
rapid
tool
improving
strategies
compared
traditional
cultivation-based
methods.
We
emphasize
importance
monitoring
mobile
genetic
elements
(MGEs),
such
integrons,
transposons,
plasmids,
bacteriophages
(phages),
relation
their
critical
role
facilitating
dissemination
determinants
via
horizontal
gene
transfer
(HGT)
across
diverse
environments
clinical
settings.
In
context,
strengths
limitations
current
bioinformatic
tools
designed
detect
AMR-associated
MGEs
metagenomic
datasets,
including
emerging
predictive
machine
learning
models,
are
evaluated.
Moreover,
controversial
phages
transmission
is
discussed
alongside
phage
therapy
promising
alternative
conventional
antibiotic
treatment.
Frontiers in Microbiomes,
Journal Year:
2024,
Volume and Issue:
3
Published: Sept. 23, 2024
The
symbiotic
relationship
between
the
gut
microbiome
and
human
body
is
a
concept
that
has
grown
in
popularity
recent
years.
Bacteriophages
(phages)
are
components
of
microbiota
their
imbalance
plays
role
pathogenesis
numerous
intestinal
disorders.
Meanwhile,
as
new
antimicrobial
agent,
phage
therapy
(PT)
offers
unique
advantages
when
compared
with
antibiotics
brings
dawn
for
treatment
multidrug-resistant
bacteria
extraintestinal
In
this
review,
we
provide
brief
introduction
to
characterization
phages,
particularly
focusing
on
newly
discovered
phages.
Additionally,
outline
involvement
phages
disease
discuss
status
challenges
utilizing
therapeutic
targets
enteric
infection.
